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REGULAR ARTICLE
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Key Points
•We present the first
in-depth analysis of
platelet PtdIns(3,4,5)P3-
binding proteins, pro-
viding a valuable
resource for future
studies.
• The PtdIns(3,4,5)P3-
binding protein, DAPP1,
negatively regulates
glycoprotein VI–driven
platelet activation and
thrombus formation.
Theclass I phosphoinositide 3-kinase (PI3K) isoformsplay important roles inplatelet priming,
activation, and stable thrombus formation. Class I PI3Kspredominantly regulate cell function
through their catalytic product, the signaling phospholipid phosphatidylinositol 3,4,5-
trisphosphate [PtdIns(3,4,5)P3], which coordinates the localization and/or activity of a
diverse range of binding proteins. Notably, the complete repertoire of these class I PI3K
effectors in platelets remains unknown, limiting mechanistic understanding of class I
PI3K–mediated control of platelet function. We measured robust agonist-driven PtdIns
(3,4,5)P3 generation in human platelets by lipidomic mass spectrometry (MS), and then used
aﬃnity-capture coupled to high-resolution proteomic MS to identify the targets of PtdIns
(3,4,5)P3 in these cells. We reveal for the ﬁrst time a diverse platelet PtdIns(3,4,5)P3
interactome, including kinases, signaling adaptors, and regulators of small GTPases, many
of which are previously uncharacterized in this cell type. Of these, we show dual adaptor for
phosphotyrosine and 3-phosphoinositides (DAPP1) to be regulated by Src-family kinases and
PI3K, while platelets from DAPP1-deﬁcient mice display enhanced thrombus formation on
collagen in vitro. This was associated with enhanced platelet a/d granule secretion and aIIbb3
integrin activation downstream of the collagen receptor glycoprotein VI. Thus, we present
the ﬁrst comprehensive analysis of the PtdIns(3,4,5)P3 signalosome of human platelets and
identify DAPP1 as a novel negative regulator of platelet function. This work provides
important new insights into how class I PI3Ks shape platelet function.
Introduction
Platelets are small, anucleate cells that play an essential role in hemostasis, but can contribute critically
to the pathogenesis of cardiovascular disease.1 Their function is coordinated by an array of cell-surface
receptors coupled to diverse intracellular signaling effectors, including class I phosphoinositide 3-
kinases (PI3Ks).2 The use of gene-targeted mice and small molecule inhibitors has revealed important
roles for the 4 class I PI3K isoforms (PI3Ka, b, d, and g) in platelet priming, activation, and thrombus
formation.3-7 PI3Kb appears to be the predominant class I isoform in platelets, being important
for glycoprotein VI (GPVI), protease-activated receptor (PAR), and P2Y12 signaling in addition to
bidirectional aIIbb3 integrin function.
6,8-10 This translates to a broad and important role for this isoform in
platelet activation and subsequent stable thrombus formation, which has attracted PI3Kb considerable
attention as a potential antithrombotic target.8,11,12 This is supported by the observation that genetic
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loss or pharmacological inhibition of PI3Kb provides protection
from occlusive arterial thrombus formation in animal models.8,9
Furthermore, AZD6482, a selective PI3Kb inhibitor, has demon-
strated promising antiplatelet effects and tolerance in humans.11,12
Thus, PI3Kb inhibition appears to afford protection from occlusive
arterial thrombosis while demonstrating limited bleeding risk,6,8,9,12
although the potential for embolization with this strategy needs
additional investigation.13,14
Despite extensive confirmation of the importance of the class I
PI3Ks to platelet function, detailed mechanistic understanding of
the events downstream of PI3K activation remains limited. Although
class I PI3Ks may have protein kinase activity15 and scaffolding
roles,16 they predominantly regulate cell function through the
product of their lipid kinase activity, phosphatidylinositol 3,4,5-
trisphosphate [PtdIns(3,4,5)P3].
17 PtdIns(3,4,5)P3 is generated by
the class I PI3K–catalyzed phosphorylation of phosphatidylinositol
4,5-bisphosphate [PtdIns(4,5)P2] and serves to coordinate the
localization and/or activity of a range of binding proteins.17-19
Known PtdIns(3,4,5)P3-binding proteins often possess a conserved
pleckstrin homology (PH) domain and span a range of protein
functional classes.17,20,21 Much of the focus with platelets has been
on the serine/threonine kinase, AKT (protein kinase B [PKB]), the
archetypal class I PI3K effector, which undergoes membrane re-
cruitment on binding of its PH domain to PtdIns(3,4,5)P3 and has
important roles in platelet function.6,22 Although a limited number of
other PtdIns(3,4,5)P3-binding proteins have received attention in
platelets,23-25 the current understanding of class I PI3K effectors
in this cell type is poor, in large part because the full repertoire
of PtdIns(3,4,5)P3-binding proteins in platelets remains unknown.
Mass spectrometry (MS) has allowed unprecedented global
insights into platelet biology in recent years26-28 and is a powerful
approach for the characterization of platelet subproteomes and
specific signaling networks. In this article, we have used MS to
conduct a detailed analysis of the PtdIns(3,4,5)P3 signalosome
of human platelets. Using lipidomic MS, we observed robust
PtdIns(3,4,5)P3 generation in response to PAR and GPVI receptor
activation. We then conducted a global, unbiased screen for
PtdIns(3,4,5)P3-binding proteins in human platelets using affinity
capture coupled to high resolution proteomic MS. Our approach iden-
tified an extensive PtdIns(3,4,5)P3 interactome, includingmany proteins
previously uncharacterized in this cell type. Of these, we define dual
adaptor for phosphotyrosine and 3-phosphoinositides (DAPP1/
Bam32/PHISH), shown previously to be an important regulator of
leukocyte function,29-33 as a Src family kinase (SFK)- and PI3K-
regulated protein that serves to restrain GPVI-mediated platelet
activation.
Materials and methods
Human platelet preparation
Venous blood anticoagulated with 4% trisodium citrate (1:10,
volume-to-volume) was obtained from healthy volunteers after
obtaining informed consent, with the approval of the local research
ethics committee at the University of Bristol. Platelets were isolated
as previously described34 with the following modifications to
minimize plasma, erythrocyte, and leukocyte contamination (Figure 2A);
(1) only the upper two-thirds of platelet-rich plasma were collected;
(2) this platelet-rich plasma was diluted with prewarmed N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid (HEPES)-Tyrode’s
medium supplemented with 0.1% (weight-to-volume) D-glucose,
10 mM indomethacin, and 0.02 U/mL apyrase (HT111) before
centrifugation; (3) platelets were washed twice in HT111 plus acid
citrate dextrose; (4) the final platelet suspension was passed through
leukocyte removal filters. Automated hematology analysis was con-
ducted to confirm the absence of detectable levels of contaminating
erythrocytes and leukocytes. The platelet suspension was allowed to
rest for 30 minutes at 30°C before use.
Identification of platelet PtdIns(3,4,5)P3-binding
proteins
Purified platelets were centrifuged (520g, 10 min, room tempera-
ture), providing an additional wash step, and the pellet lysed in ice-
cold lysis buffer (20 mM HEPES [pH 7.4], 120 mM NaCl, 0.5%
NP40, 5 mM EGTA, 5 mM EDTA, 5 mM b-glycerophosphate,
10 mM NaF, 1 mM sodium orthovanadate, cOmplete mini protease
inhibitor tablet [Roche]). Phosphatase inhibitors were included to
preserve the identity of PtdIns(3,4,5)P3 on the beads.
19 Lysates
were freeze-thawed, vortexed, and centrifuged (12 000g, 10 min,
4°C) to provide final clarified samples. A total of 8 3 108 platelets
were used per sample for proteomics experiments. Affinity capture
was performed by incubating lysates with control or PtdIns(3,4,5)P3-
coupled beads for 90 minutes at 4°C. Additional control lysates
were preincubated with 40 mM free PtdIns(3,4,5)P3 for 30 minutes
prior to PtdIns(3,4,5)P3 bead incubation. Beads were washed 3
times with lysis buffer, and proteins were eluted in NuPAGE LDS
sample buffer (plus 50 mM dithiothreitol). Eluates were subjected to
western blotting, or the proteins were fractionated by gel walking,
trypsin digested, and the resulting peptides fractionated using an
Ultimate 3000 nano–high-performance liquid chromatography (HPLC)
system in line with an Orbitrap Fusion Tribrid mass spectrometer.
The MS data have been deposited to the ProteomeXchange
Consortium via the PRIDE35 partner repository with the data set
identifier PXD003777.
Mice
Animal studies were approved by the local research ethics committee
at the University of Bristol, and mice were bred and maintained under a
UKHomeOffice project license (PPL30/2908).Generation of DAPP12/2
(knockout [KO]) mice has been previously described.36 Experiments
were performed on C57BL/6 DAPP12/2 mice from heterozygote
breeders, with wild-type littermate controls sex-matched where pos-
sible. Blood was obtained by cardiac puncture of sacrificedmice, and
washed platelets were prepared as previously described.37
In vitro thrombus formation
In vitro thrombus formation assays were performed under non-
coagulating conditions, as previously described.38 Mouse blood
was drawn by cardiac puncture into a syringe containing 4% trisodium
citrate (1:10, volume-to-volume), 2 U/mL heparin, and 40 mM PPACK.
Samples were imaged by using a 403 oil immersion objective on a
Leica DM IRE2 inverted epifluorescent microscope attached to a Leica
TCS-SP2-AOBS confocal laser scanning microscope. Quantification
was performed by using Volocity 6.1.1 Quantitation software.
Aggregometry
Platelet aggregation assays were performed as previously de-
scribed.4 Briefly, washed platelets at 23 108/mL were stimulated
with agonist while monitoring for aggregation by using a Chronolog
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490-4D aggregometer at 37°C with continuous stirring at
1200 rpm.
Flow cytometry analysis
Flow cytometry analysis of platelets was performed as previously
described.5 Samples were analyzed on a BD FACSCanto II by
using FACSDiva software (10 000 platelet events per sample).
Subsequent analysis was performed by using Flowing Software 2.5.
Additional details are provided in supplemental Methods.
Results
Characterizing the PtdIns(3,4,5)P3 signalosome of
human platelets
Class I PI3K activation in platelets is most commonly inferred from
the phosphorylation status of the downstream effector, AKT,39
which in turn propagates signal transduction via the regulation of
its substrates, including GSK3 and PRAS4022,40 (Figure 1A-C).
Recently, Clark et al41,42 developed a new method for the direct and
sensitive measurement of cellular phosphoinositides by MS,
including quantification of the specific molecular (fatty acyl) species
of the class I PI3K catalytic product, PtdIns(3,4,5)P3. We applied
this lipidomic approach to human platelets and observed robust
generation of stearoyl/arachidonoyl (C38:4 or C18:0/C20:4)
PtdIns(3,4,5)P3 in response to PAR or GPVI activation with thrombin
or collagen-related peptide (CRP), respectively (Figure 1D). Notably,
we were also able to quantify the less abundant C38:3 PtdIns(3,4,5)P3
in human platelets for the first time, the behavior of which mirrored the
C38:4 form, in addition to multiple species of PtdInsP2 (supplemental
Figure 1A-B).
Upon confirming robust PtdIns(3,4,5)P3 generation in human
platelets, we sought to better understand how this phosphoinosi-
tide permits class I PI3K to regulate multiple, diverse aspects of
platelet function. PtdIns(3,4,5)P3 is considered to regulate cell
function predominantly through the recruitment and/or regulation of
a range of binding proteins,17,19 the full platelet repertoire of which
remains unknown. We were recently able to confirm the RAS/RAP-
GAP, RASA3, as a platelet PtdIns(3,4,5)P3-binding protein by using
PtdIns(3,4,5)P3 immobilized on agarose beads.
43 We therefore
set out to develop this affinity capture strategy to conduct the first
high-resolution, global, unbiased proteomic analysis of the com-
plete PtdIns(3,4,5)P3 interactome of human platelets. To do this, we
developed a modified human platelet preparation protocol to
minimize sample contamination with proteins derived from plasma
or contaminating blood cells (Figure 2A), utilizing freshly isolated
platelets to avoid proteome degradation.27 First, the eluates from
affinity capture experiments with platelet lysates were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
viewed by SYPRO Ruby gel staining. This revealed protein bands
present specifically in PtdIns(3,4,5)P3 bead eluates (Figure 2B),
suggesting our approach could successfully capture a number of
human platelet PtdIns(3,4,5)P3-binding proteins. To obtain an in-
depth PtdIns(3,4,5)P3 interactome, we reduced sample com-
plexity and increased resolution by incorporating a gel walking
step for protein fractionation and subjecting our samples to
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analysis on an Orbitrap Fusion Tribrid mass spectrometer.
Because only a proportion of the proteins captured on the beads
were likely to be genuine PtdIns(3,4,5)P3-regulated proteins,
in addition to using blank beads, we incorporated additional
control samples preincubated with competing PtdIns(3,4,5)P3
to confirm binding specificity and used label-free Top 3 Protein
Quantification (T3PQ) of the MS data.44 This dual-controlled
quantitative approach validated the specificity and reproducibility
of our method across independent donors (Figure 2C) and
enabled us to apply highly stringent filtering criteria to the
proteomics data to define the human platelet PtdIns(3,4,5)P3
interactome.
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Dissecting the platelet PtdIns(3,4,5)P3 interactome
Our analysis reveals an extensive platelet PtdIns(3,4,5)P3 inter-
actome, including.40 proteins previously reported to show affinity
for PtdIns(3,4,5)P3 in other cell types or in vitro assays (Table 1;
supplemental Table 1). Indeed, our data set spans extensively
established class I PI3K effectors, such as BTK, TEC, PDK1, and
AKT,18 to additional proteins with previously reported PtdIns(3,4,5)
P3 affinity, including RASA3, DAPP1, cytohesin 1-3, PHLDB1,
DOCK and ELMO proteins, ADAP1, myosin 1G, SNX9, and
TBC1D2B,20,45-53 the majority of which remain functionally uncharac-
terized in platelets. We also identified several potentially novel class
I PI3K–regulated proteins, including FRMD4B, ARHGAP6, APPL2,
and GRTP1. Furthermore, ARAP1,54 TNFAIP8 family proteins,55
SIN1,56 and P-REX1,57 all of which have reported PtdIns(3,4,5)P3
affinity, were also captured on our PtdIns(3,4,5)P3 beads, although
falling below our stringent filtering criteria, further confirming the
comprehensive nature of our approach.
Ontology analysis58,59 revealed the enrichment of molecular func-
tions and biological processes associated with class I PI3K,17,20,21
including regulation of small GTPase function (eg, cytohesin 1-3,
ADAP1, and DOCK and ELMO proteins), intracellular transport (eg,
adenosine 59-diphosphate[ADP]-ribosylation factor [ARF]-guanine
nucleotide exchange factors [GEFs]/GTPase-activating proteins
[GAPs], MYO1G, and SNX9), signaling adaptors (eg, DAPP1,
GAB1-3, and SKAP2), and kinases or phosphatases involved in
phosphorylation events (eg, BTK, TEC, PDK1, and AKT) (supple-
mental Figure 2A). Enrichment analysis also confirmed the abundance
of proteins bearing PH domains in our data set in addition to further
protein domains associated with PtdIns(3,4,5)P3 binding and general
cell signaling/adaptor function (supplemental Figure 2B). Analysis of
our data set through literature searching and high-confidence
network analysis using STRING60 suggested the majority of proteins
were directly captured on the PtdIns(3,4,5)P3 beads, while also con-
firming a number to be present by virtue of protein-protein interactions
as part of the wider PtdIns(3,4,5)P3 signalosome (supplemental
Figure 3). These include AP-2 complex components/partners (eg,
AP-2m1, EPS15, and Stonin-2, potentially via AP-2a161), cytoskeletal
components (eg, tubulin-b1 and tubulin-a4A), and protein chaperones
(eg, HSP90a and TCP-1 complex components). Notably, FRMD4B,
which lacks a signature PtdIns(3,4,5)P3-binding motif but has been
reported to associate with cytohesin family proteins, was captured in
abundance.62,63 Having previously identified a role for cytohesin-2 in
platelet secretion,64 we hypothesized that FRMD4B may have been
captured through its interaction with this ARF-GEF. In confirmation of
this, we revealed an agonist-insensitive association of these proteins
in human platelets (supplemental Figure 4), identifying a novel con-
stitutive complex in this cell type.
DAPP1 is regulated by phosphoinositides and
tyrosine phosphorylation in platelets
We verified the capture of a spectrum of proteins identified in our
proteomics screen by western blotting (Figure 3A), including a
number for which expression in human platelets has not previously
been confirmed. By reference to the input material used for these
experiments, this blotting also has the potential to provide more
insight into the relative affinity of the proteins for PtdIns(3,4,5)P3
under our experimental conditions. In agreement with our pro-
teomics data, proteins such as BTK, RASA3, and DAPP1 were
captured in abundance, whereas others, such as ARAP1, were
detectable in the bead eluates at lower levels, in line with previously
reported affinity data.30,54,65,66 We also confirmed the capture of
proteins utilizing liposomes comprising PtdIns(3,4,5)P3 in combi-
nation with the membrane glycerophospholipids, phosphatidyleth-
anolamine and phosphatidylcholine, further validating our proteomics
approach (supplemental Figure 5B).
Of the 3 most abundantly identified platelet PtdIns(3,4,5)P3-binding
proteins in our proteomics screen, BTK has been shown previously
to have a role in GPVI-mediated platelet activation,24 while we have
recently revealed a role for RASA3 in integrin aIIbb3 outside-
in signaling.43 In contrast, the role of the PH and SH2 domain–
containing DAPP1 in platelets remains unknown, despite important
roles in multiple other cell types of hematopoietic origin.33,36,67-69
Some proteins are known to be regulated by multiple phosphoi-
nositides, and PtdIns(3,4,5)P3 can be dephosphorylated by
5-phosphatases, such as SHIP1, to yield phosphatidylinositol
3,4-bisphosphate [PtdIns(3,4)P2],
18,70 which can act in concert
with PtdIns(3,4,5)P3 to regulate a subset of class I PI3K effectors,
such as AKT.71 We confirmed that human platelet DAPP1 shows
affinity for PtdIns(3,4)P2 in addition to PtdIns(3,4,5)P3 (Figure 3B),
in agreement with the reported dual specificity of the DAPP1 PH
domain.45 Additional proteins identified in our screen with the
potential to be regulated by other phosphoinositides include
PHLDB1,45 TAPP1/2,47 and SNX9.72,73
Upon stimulation of platelets with either thrombin or CRP, we
observed a molecular weight shift in DAPP1 by western blotting
(Figure 3C) and a PI3K-dependent increase in the proportion
of DAPP1 present in the platelet membrane fraction (Figure 3D).
The molecular weight shift is consistent with that observed for
DAPP1 tyrosine phosphorylation in other cell types31,74,75 and was
confirmed by western blotting of DAPP1 immunoprecipitates with
the 4G10 antibody. This suggested that DAPP1 is recruited to
membrane PtdIns(3,4,5)P3/PtdIns(3,4)P2 and tyrosine phosphory-
lated in activated platelets, and indeed the phosphorylation was
dependent on both PI3K and SFK activity (Figure 4A). Furthermore,
the P2Y12 inhibitor, AR-C66096, and the clinically used integrin
aIIbb3 antagonist, Abciximab, also inhibited DAPP1 tyrosine
phosphorylation at this later time point (Figure 4A), revealing that
ADP and integrin outside-in signaling contribute to DAPP1 phos-
phorylation in platelets, most likely through consolidation of PI3K
activation.6 To investigate whether activation of PI3K alone is
sufficient for DAPP1 tyrosine phosphorylation, we treated platelets
with the primers, thrombopoietin and insulin-like growth factor-1,
which signal to PI3K without triggering full platelet activation.3-5
Despite inducing a PI3K response, neither was able to induce
DAPP1 tyrosine phosphorylation (Figure 4B), revealing differential
integration of PI3K and SFK signaling downstream of platelet
primers and full agonists.
DAPP1-deficient mice display increased platelet
activation and thrombus formation
We established that mouse platelets express DAPP1, and that
it undergoes thrombin- and CRP-induced tyrosine phosphorylation,
as observed in human platelets (Figure 4C). We confirmed DAPP1
was absent from the platelets of DAPP12/2 mice and that
these animals exhibit normal hematological parameters (Figure 4D;
supplemental Table 2), and we set out to define the role of this
protein in platelet activation and thrombus formation. Activation by
924 DURRANT et al 13 JUNE 2017 x VOLUME 1, NUMBER 14
collagen exposed after blood vessel injury is a critical early event in
platelet activation,76 and so we initially performed in vitro thrombosis
experiments flowing whole blood over a collagen-coated surface
under noncoagulating conditions. Strikingly, we observed increased
thrombus surface coverage with blood from DAPP12/2 mice
compared with wild-type controls (Figure 5A). Given the essential
role of GPVI in initial platelet activation in this context76 and the well-
described importance of class I PI3K in this pathway,9,10,77,78 we
investigated platelet function downstream of this collagen receptor
by assessing CRP-induced platelet aggregation. In line with our
observations for thrombus formation, GPVI-mediated aggregation
was significantly enhanced in DAPP12/2 platelets (Figure 5B),
suggesting that DAPP1 acts to restrain collagen-induced platelet
activation.
A similar negative regulatory role for DAPP1 has been reported in
mast cells, where it acts to limit FceRI-induced granule release.67 To
determine whether the elevated functional responses of DAPP12/2
platelets might correspond to a similar enhancement of granule
release, we conducted fluorescence-activated cell sorting (FACS)
analysis and luminometry to assess platelet secretion. Compared
with wild-type controls, DAPP12/2 platelets displayed significantly
enhanced P-selectin exposure and ATP release in response to CRP
(Figure 6A-B), confirming enhanced a and d granule secretion,
respectively. We also observed a significant increase in GPVI-
mediated platelet integrin aIIbb3 activation in the absence of DAPP1
(Figure 6C), which was blocked in the presence of the PI3K
inhibitor, wortmannin (Figure 6D). Although DAPP12/2 mast cells
were reported to display changes in calcium mobilization and
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Figure 3. Validation of the proteomics screen and characterization of DAPP1 as a PtdIns(3,4,5)P3- and PtdIns(3,4)P2-binding protein. (A) Human platelet lysates were
incubated with control or PtdIns(3,4,5)P3-coupled beads for 90 minutes at 4°C, with (1) or without preincubation with competing free PtdIns(3,4,5)P3, before washing, elution,
and western blotting analysis for a range of proteins identified in the proteomics screen. (B) Human platelet lysates were incubated with either PtdIns(3,4)P2- or PtdIns(3,4,5)P3-coupled
beads as in panel A, and eluates were subjected to western blotting for DAPP1. (C) Human platelets were stimulated with 0.2 U/mL thrombin or 5mg/mL CRP for the indicated
times, and lysates were blotted as indicated. The arrows indicate the molecular weight shift observed for DAPP1. (D) Human platelets stimulated with (i) thrombin (aT, 0.2 U/mL, 5 min) or
(ii) CRP (5 mg/mL, 5 min) after 10 minutes of preincubation with dimethyl sulfoxide (DMSO) or 100 nM WTM were subjected to ultracentrifuge fractionation. Cytosol and membrane
fractions were blotted as indicated. Histograms represent densitometry of blots from 3 independent experiments 1 standard error of the mean. Statistical analyses were performed
by using 2-way analysis of variance with Bonferroni post-tests. *P , .05; **P , .001. Ctl, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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phosphorylation of AKT and ERK,67 these parameters were not
significantly altered in CRP-treated DAPP12/2 platelets (supple-
mental Figure 6A-B). Similarly, we observed no significant changes
to the CRP-induced phosphorylation status of proximal GPVI
signaling components (supplemental Figure 7), although we did
detect small but significant changes in the surface expression of
GPVI and GP1ba on DAPP12/2 platelets (supplemental Figure 8).
In contrast to GPVI-mediated platelet function, we saw a modest
decrease in PAR4-AP–induced platelet aggregation in DAPP12/2
mice, whereas a and d granule secretion and aIIbb3 integrin acti-
vation were unchanged in response to this agonist (supplemental
Figure 9). Taken together, these results reveal that the class I PI3K
effector, DAPP1, restrains platelet function downstream of GPVI,
thus identifying a novel negative regulator of collagen-driven platelet
activation and thrombus formation.
Discussion
Class I PI3K is an important signaling hub in human and mouse
platelets, with key roles in platelet priming, activation, and stable
thrombus formation, thought to be orchestrated primarily through
the action of its catalytic product, PtdIns(3,4,5)P3. Direct mea-
surements of PtdIns(3,4,5)P3 in platelets have traditionally involved
the use of radiolabeled precursors and HPLC,9,79,80 yet this
approach is laborious and provides no information about the fatty
acyl content of this phosphoinositide.42 Although PtdIns(3,4,5)P3
has been previously measured in platelets by lipidomic MS, this
measurement has lacked sensitivity, detecting this phosphoinosi-
tide only in response to a high concentration of thrombin.81 Our
lipidomic analysis revealed a basal, wortmannin-sensitive level of
PtdIns(3,4,5)P3 in human platelets in addition to robust thrombin-
and CRP-driven PtdIns(3,4,5)P3 generation. We focused on
the stearoyl/arachidonoyl species of PtdIns(3,4,5)P3, generally
the most abundant molecular species in primary mammalian
tissues,41,42,82,83 but we were also able to measure the less abundant
C38:3 form. Conventional effectors associate with PtdIns(3,4,5)P3
primarily via its phosphorylated headgroup, and a comparison
of PtdIns(3,4,5)P3-binding proteins purified by our approach and
others19,20,48,84,85 suggests that most are unlikely to show
absolute species specificity. However, it is possible that
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Figure 4. DAPP1 is tyrosine phosphorylated in response to human andmouse platelet activation. (A) Western blotting of DAPP1 immunoprecipitates (IP) with the 4G10
antibody after thrombin (0.2 U/mL) or CRP (5 mg/mL) stimulation of human platelets for 5 minutes, after 10 minutes of preincubation with either Veh, WTM (100 nM), PP1
(10 mM), AR-C66096 (ARC, 1 mM) or Abciximab (Abcx, 1 mg/mL). The arrow indicates the position of tyrosine phosphorylated (pY) DAPP1. Corresponding whole-cell lysates
were blotted for total AKT to confirm input loading and for AKT phosphorylation and global tyrosine phosphorylation to confirm the action of the agonists and inhibitors.
(B) Western blotting of DAPP1 immunoprecipitates after treatment of human platelets for 5 minutes with the platelet primers, thrombopoietin (200 ng/mL), insulin-like growth factor-1
(200 nM), or the agonists described in panel A. (C) DAPP1 immunoprecipitates from mouse platelets stimulated for 5 minutes with CRP (10mg/mL) or thrombin (aT, 0.5 U/mL) were blotted
for 4G10 (pY) and DAPP1. (D) DAPP1 expression in wild-type (WT) and DAPP12/2 (KO) mouse platelets. Results are representative of at least 3 independent experiments.
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PtdIns(3,4,5)P3 molecular species identity contributes to the
fine tuning of binding protein localization and/or function in
vivo.
Although a number of PtdIns(3,4,5)P3-binding proteins have been
isolated from other cell types,19,47,84-86 knowledge of these PI3K
effectors in platelets prior to this study was poor, with attention
primarily focused on AKT. Although our data demonstrate that AKT
phosphorylation serves as a good readout for PtdIns(3,4,5)P3
generation in thrombin- and CRP-activated platelets (Figure 1),
AKT is not responsible for driving all class I PI3K–regulated pro-
cesses in cells and may be disconnected from class I PI3K in some
contexts.87-89 Indeed, although AKT isoforms have important
roles in platelets,6 other PtdIns(3,4,5)P3-binding proteins mediate
key aspects of platelet biology, including platelet-specific
functions.23-25,43 This highlights the need to define the individual
repertoires of class I PI3K effectors in highly specialized cell types,
and our study reveals for the first time the extensive network of
PtdIns(3,4,5)P3-binding proteins in platelets. Strikingly, although
well-characterized PtdIns(3,4,5)P3 effectors, such as AKT, BTK, and
PDK1, have been shown to play roles in platelet activation and
thrombus formation,6,23,24,39 the majority of proteins identified in our
screen have undergone no characterization in platelets thus far, and
this work provides the first insight into their function in these cells.
Furthermore, we identified proteins that have received limited
characterization in any tissue type, including IPCEF1, GRTP1, and
TBC1D2B.
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Figure 5. Platelets from DAPP12/2 mice are hyperresponsive
to collagen-driven functional responses. (A) Whole blood from
WT or DAPP12/2 (KO) mice was loaded with DIOC6 and flowed over
collagen (1000 s21, 3 min) before fixation and imaging by confocal
microscopy; (i) representative images of z-slices at indicated intervals
relative to the thrombus base; (ii) histogram of surface coverage; (iii)
histogram of thrombus height. n 5 5 1 standard error of the mean.
(B) CRP-mediated platelet aggregation in WT and DAPP12/2 mouse
platelets; (i) representative aggregation trace; (ii) histogram of the
percentage of aggregation in response to a range of indicated CRP
concentrations. n 5 6 1 standard error of the mean. Statistical
analyses were performed by using Student t tests (A) or 2-way analysis
of variance with Bonferroni post-tests (B). *P , .05; **P , .001.
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The abundance of identified proteins involved in small GTPase
regulation reflects a range of GEFs and GAPs in our signalosome, a
number of which have previously reported affinity for PtdIns(3,4,5)
P3.
46,48,51,54,66 The targets of these proteins include RHO and ARF
family small GTPases, several of which play key roles in platelet
function.90-92 Notably, current understanding of how these small
GTPases are controlled by GEFs/GAPs in platelets is poor, yet the
latter are often crucial for coupling PI3K to the regulation of cell
function in other cell types. Indeed, based on work in other
cells,19,53,91,93,94 several of the PtdIns(3,4,5)P3-binding GEFs/GAPs
identified are likely to regulate cytoskeletal dynamics and protein
trafficking in platelets in concert with other proteins identified, such as
myosin 1G50 and SNX9.95 The identification of TNFAIP8 family
proteins and SIN1 may permit important new insights into events such
as phosphoinositide trafficking55 and mTORC2 activation,56 respec-
tively, in platelets, whereas proteins such as FRMD4B, IPCEF1, and
SKAP2 are likely to hold roles as signaling adaptors in this cell type.
The individual characterization of proteins identified in this screen by
our laboratory and others will allow determination of their functional
roles in the class I PI3K/PtdIns(3,4,5)P3 pathway in platelets and
other cell types. Indeed, in recent work, we have identified a key role
for the PtdIns(3,4,5)P3-binding RAS/RAP-GAP, RASA3, in aIIbb3
outside-in signaling,43 and in this article, we define an important role
for the SH2 and PH domain–containing adaptor protein, DAPP1, in
GPVI signaling. DAPP1 has previously been shown to play both
positive and negative regulatory roles, dependent on the cellular and
stimulatory context.33 In B cells, DAPP1 deficiency results in impaired
B-cell receptor signaling, leading to a proliferation defect in vitro,36
impaired antigen responses,68 and increased apoptosis in late-stage
germinal centers in vivo,69 while DAPP1-deficient T cells display impaired
in vitro proliferation and interleukin 4 (IL-4) production.96 Conversely,
DAPP1-deficient B cells are hyperresponsive to IL-4 or CD40
stimulation,69 while splenic cells from trypanosome-infected DAPP1-
deficient mice display increased production of the proinflammatory
cytokines, IFN-g, TNF-a, and IL-6.97 Similarly, mast cells lacking
DAPP1 display enhanced degranulation and IL-6 production.67
Our work reveals that DAPP1 is regulated by PI3K andSFKs in platelets
in a manner analogous to other cell types31,74,75 and acts to restrain
GPVI-mediated platelet function in a negative regulatory role compa-
rable to that observed in mast cells downstream of the high-affinity
immunoglobulin E receptor, FceRI.67 The specificity of the DAPP1
phenotype to GPVI signaling in platelets is in line with the critical
importance of class I PI3K function to this pathway,9,77,78 and the ability
of DAPP1 to hold a specific positive or negative role, depending on the
signaling context, appears to be a common feature of such adaptor
proteins in blood cells.33 Our data demonstrate that the DAPP12/2
platelet phenotype is not due to overt changes in proximal GPVI
signaling, suggesting that DAPP1 may contribute to platelet function
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Figure 6. Platelets from DAPP12/2 mice are hyperresponsive to
GPVI stimulation. (A) FACS analysis of P-selectin exposure on WT
and DAPP12/2 (KO) mouse platelets in response to CRP (10 min).
n 5 9 1 standard error of the mean. (B) ATP release by WT and
DAPP12/2 mouse platelets in response to CRP. Data are expressed
as peak ATP release as a percentage of a standard. n 5 5 1 standard
error of the mean. (C) FACS analysis of integrin aIIbb3 activation on WT
and DAPP12/2 mouse platelets in response to CRP (10 min). n 5 9 1
standard error of the mean. (D) Integrin aIIbb3 activation on WT and
DAPP12/2 mouse platelets in response to CRP (5 mg/mL, 10 min) after
preincubation for 10 minutes with either vehicle, WTM (100 nM), or
AR-C66069 (ARC, 1 mM). FACS fluorescence intensities (A, C-D) were
normalized to the response to maximal agonist concentration averaged
per mouse pair (WT and DAPP1 KO) to preserve sample variance at
the maximal concentration. Statistical analyses were performed by using
2-way analysis of variance with Bonferroni post-tests. *P , .05;
**P , .001; ***P , .0001.
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and secretion further downstream or in a parallel pathway. Previous
work has demonstrated the tyrosine phosphorylation of DAPP1 to be
important for its function, including roles in receptor internalization
and endosomal sorting.29,33,98,99 Interestingly, we did observe small
reductions in cell surface receptor expression. Although unlikely to fully
explain our observed phenotype, this data may support a role for
DAPP1 in platelet receptor trafficking, which could be facilitated by its
dual affinity for PtdIns(3,4,5)P3 and PtdIns(3,4)P2.
71 The identification
of DAPP1 interacting partners and the advent of novel lipidomic
approaches permitting more acute quantitative assessment of the
PtdIns(3,4,5)P3/PtdIns(3,4)P2 balance in primary cells will allow greater
understanding of how DAPP1 regulates cell function.
In conclusion, we have carried out an in-depth analysis of the
platelet PtdIns(3,4,5)P3 signalosome by MS, yielding new insights
into the molecular identity of PtdIns(3,4,5)P3 in human platelets and
providing the first detailed analysis of the PtdIns(3,4,5)P3 inter-
actome of these cells. The latter provides an important resource for
future studies, facilitating work to further dissect how class I PI3Ks
mediate diverse and important aspects of cell function. Indeed, it has
allowed us to identify DAPP1 as a new PI3K-regulated player in GPVI-
mediated platelet activation and an important negative regulator of
collagen-mediated thrombus formation. Furthermore, given the
challenges and limitations of directly targeting the proximal, ubiquitous,
and multifunctional class I PI3Ks for therapeutic means,13,14 the
characterization of downstream effectors may provide novel targets100
for the regulation of specific aspects of platelet signaling and function.
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